News | February 06, 2025
JB Pharma reports revenue growth of 14% in Q3 FY25; Net profit up by 22%
Profit after Taxes registered strong growth of 22% to Rs. 162 crores versus Rs. 134 crores in Q3 FY24
Profit after Taxes registered strong growth of 22% to Rs. 162 crores versus Rs. 134 crores in Q3 FY24
The group reported Q3FY25 operating revenue of Rs 3,821 crore, driven by sustained double-digit growth of 14 per cent in biosimilars
The company said it voluntarily paused production at the Gagillapur plant in September 2024 for risk assessment on account of the USFDA observations
In 2023, Endox had revenues of approximately SEK 65 million
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
Stable profits, low leverage to keep credit profiles comfortable
Konieczny has served as Interim CEO since April 2024
The company is also looking at an inorganic opportunity over the next two years to have a commercially ready footprint in the US
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
The comprehensive criteria encompasses evaluation of debt management, sales growth, earnings-per-share performance, as well as returns on equity
Subscribe To Our Newsletter & Stay Updated
